## Roberto Perrone

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/200252/publications.pdf

Version: 2024-02-01

112 papers 3,522 citations

35 h-index 51 g-index

113 all docs

113 docs citations

113 times ranked 3441 citing authors

#	Article	IF	CITATIONS
1	Why PB28 Could Be a Covid 2019 Game Changer?. ACS Medicinal Chemistry Letters, 2020, 11, 2048-2050.	1.3	6
2	An innovative small molecule for promoting neuroreparative strategies. RSC Advances, 2018, 8, 5451-5458.	1.7	3
3	Structure-activity relationship study towards non-peptidic positron emission tomography (PET) radiotracer for gastrin releasing peptide receptors: Development of [18F] (S)-3-(1H-indol-3-yl)-N-[1-[5-(2-fluoroethoxy)pyridin-2-yl]cyclohexylmethyl]-2-methyl-2-[3-(4-nitrophenyl)ureido]p Bioorganic and Medicinal Chemistry, 2017, 25, 277-292.	pro <mark>fi</mark> dnam	ide. <sup>4</sup>
4	Targets for Drug Therapy for Autism Spectrum Disorder: Challenges and Future Directions. Journal of Medicinal Chemistry, 2017, 60, 9114-9141.	2.9	46
5	Radiosynthesis and <i>inÂvivo</i> Evaluation of Carbonâ€11 (2 <i>S</i> )â€3â€{1 <i>H</i> ê4ndolâ€3â€yl)â€2â€{[(4â€methoxyphenyl)carbamoyl]amino}â€ <i>N</i> â612â€{[1â€an Attempt to Visualize Brain Formyl Peptide Receptors in Mouse Models of Neuroinflammation. Chemistry and Biodiversity, 2016, 13, 875-883.	(5â€metho	oxypyridinâ(2)
6	Structural modifications of the serotonin 5-HT7 receptor agonist N-(4-cyanophenylmethyl)-4-(2-biphenyl)-1-piperazinehexanamide (LP-211) to improve inÂvitro microsomal stability: A case study. European Journal of Medicinal Chemistry, 2016, 120, 363-379.	2.6	14
7	Functionalized Coumarine Fragment to Obtain Fluorescent and Selective Pâ€Glycoprotein Ligands. Archiv Der Pharmazie, 2016, 349, 161-167.	2.1	3
8	Arylpiperazine agonists of the serotonin 5-HT1A receptor preferentially activate cAMP signaling versus recruitment of $\hat{l}^2$ -arrestin-2. Bioorganic and Medicinal Chemistry, 2015, 23, 4824-4830.	1.4	16
9	From mixed sigma-2 receptor/P-glycoprotein targeting agents to selective P-glycoprotein modulators: Small structural changes address the mechanism of interaction at the efflux pump. European Journal of Medicinal Chemistry, 2015, 89, 606-615.	2.6	13
10	Design, Synthesis, Lipophilic Properties, and Binding Affinities of Potential Ligands in Positron Emission Tomography (PET) for Visualization of Brain Dopamine D <sub>4</sub> Receptors. Chemistry and Biodiversity, 2014, 11, 299-310.	1.0	5
11	SAR study on arylmethyloxyphenyl scaffold: Looking for a P-gp nanomolar affinity. European Journal of Medicinal Chemistry, 2014, 76, 558-566.	2.6	12
12	Design, synthesis, radiolabeling and in vivo evaluation of potential positron emission tomography (PET) radioligands for brain imaging of the 5-HT7 receptor. Bioorganic and Medicinal Chemistry, 2014, 22, 1736-1750.	1.4	22
13	SAR Studies on Tetrahydroisoquinoline Derivatives: The Role of Flexibility and Bioisosterism To Raise Potency and Selectivity toward P-glycoprotein. Journal of Medicinal Chemistry, 2014, 57, 9983-9994.	2.9	26
14	Trimethoxybenzanilide-Based P-Glycoprotein Modulators: An Interesting Case of Lipophilicity Tuning by Intramolecular Hydrogen Bonding. Journal of Medicinal Chemistry, 2014, 57, 6403-6418.	2.9	23
15	Novel Derivatives of 1-Cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]piperazine (PB28) with Improved Fluorescent and $if$ Receptors Binding Properties. Journal of Medicinal Chemistry, 2014, 57, 3314-3323.	2.9	18
16	PET Radiotracers for Imaging Pâ€glycoprotein: The Challenge for Early Diagnosis in AD. ChemMedChem, 2014, 9, 38-42.	1.6	6
17	Synthesis, radiolabeling and inÂvivo evaluation of [11C](R)-1-[4-[2-(4-methoxyphenyl)phenyl]piperazin-1-yl]-3-(2-pyrazinyloxy)-2-propanol, a potential PET radioligand for the 5-HT7 receptor. European Journal of Medicinal Chemistry, 2014, 79, 152-163.	2.6	26
18	Comparative evaluation of two dye probes in the rat everted gut sac model for unambiguous classification of P-gp substrate and inhibitor. Journal of Pharmacological and Toxicological Methods, 2013, 67, 5-8.	0.3	6

#	Article	IF	Citations
19	Development of 3,4-dihydroisoquinolin-1(2H)-one derivatives for the Positron Emission Tomography (PET) imaging of $\sharp f$ 2 receptors. European Journal of Medicinal Chemistry, 2013, 69, 920-930.	2.6	42
20	Sigmaâ€2 Receptor Agonists as Possible Antitumor Agents in Resistant Tumors: Hints for Collateral Sensitivity. ChemMedChem, 2013, 8, 2026-2035.	1.6	52
21	Investigation of $\ddot{l}f$ receptors agonist/antagonist activity through N-(6-methoxytetralin-1-yl)- and N-(6-methoxynaphthalen-1-yl)alkyl derivatives of polymethylpiperidines. Bioorganic and Medicinal Chemistry, 2013, 21, 1865-1869.	1.4	8
22	Novel highly potent serotonin 5-HT7 receptor ligands: Structural modifications to improve pharmacokinetic properties. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 6083-6086.	1.0	6
23	Activity–lipophilicity relationship studies on P-gp ligands designed as simplified tariquidar bulky fragments. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 3728-3731.	1.0	11
24	Towards metabolically stable 5-HT7 receptor ligands: a study on 1-arylpiperazine derivatives and related isosters. Experimental Brain Research, 2013, 230, 569-582.	0.7	14
25	Naphthalenyl derivatives for hitting P-gp/MRP1/BCRP transporters. Bioorganic and Medicinal Chemistry, 2013, 21, 1324-1332.	1.4	26
26	Potent and selective tariquidar bioisosters as potential PET radiotracers for imaging P-gp. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 1370-1374.	1.0	6
27	Guinea-pig ileum as ex vivo model useful to characterize ligands displaying Imidazoline I2 and Adrenergic alpha2 mixed activity: a preliminary study. Drugs and Therapy Studies, 2013, 3, 1.	0.6	0
28	Classes of Sigma2 (σ2) Receptor Ligands: Structure Affinity Relationship (SAfiR) Studies and Antiproliferative Activity. Current Pharmaceutical Design, 2012, 18, 938-949.	0.9	37
29	2â€Aminopyridine Derivatives as Potential σ <sub>2</sub> Receptor Antagonists. ChemMedChem, 2012, 7, 1847-1857.	1.6	22
30	Potent Galloyl-Based Selective Modulators Targeting Multidrug Resistance Associated Protein 1 and P-glycoprotein. Journal of Medicinal Chemistry, 2012, 55, 424-436.	2.9	34
31	Investigations on the 1-(2-Biphenyl)piperazine Motif: Identification of New Potent and Selective Ligands for the Serotonin7(5-HT7) Receptor with Agonist or Antagonist Action in Vitro or ex Vivo. Journal of Medicinal Chemistry, 2012, 55, 6375-6380.	2.9	35
32	The therapeutic potential of 5-HT1A receptors: a patent review. Expert Opinion on Therapeutic Patents, 2012, 22, 887-902.	2.4	36
33	A Benzopyrane Derivative as a Pâ€Glycoprotein Stimulator: A Potential Agent to Decrease βâ€Amyloid Accumulation in Alzheimer's Disease. ChemMedChem, 2012, 7, 391-395.	1.6	14
34	Fluorescent Derivatives of $If$ Receptor Ligand 1-Cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]piperazine (PB28) as a Tool for Uptake and Cellular Localization Studies in Pancreatic Tumor Cells. Journal of Medicinal Chemistry, 2011, 54, 5858-5867.	2.9	35
35	Analogues of If Receptor Ligand 1-Cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]piperazine (PB28) with Added Polar Functionality and Reduced Lipophilicity for Potential Use as Positron Emission Tomography Radiotracers, Journal of Medicinal Chemistry, 2011, 54, 1022-1032.	2.9	45
36	A new generation of MDR modulating agents with dual activity: P-gp inhibitor and iNOS inducer agents. Toxicology in Vitro, 2011, 25, 222-230.	1.1	15

3

#	Article	IF	CITATIONS
37	EGFR tyrosine kinase inhibitors and multidrug resistance: perspectives. Frontiers in Bioscience - Landmark, 2011, 16, 1811.	3.0	15
38	Clinical Pharmacokinetic and Metabolism of PET Radiotracers for Imaging P-glycoprotein in Chemoresistant Tumor of Colorectal Cancer. Current Drug Metabolism, 2011, 12, 985-988.	0.7	8
39	Modulation and Absorption of Xenobiotics: The Synergistic Role of CYP450 and P-gp Activities in Cancer and Neurodegenerative Disorders. Current Drug Metabolism, 2011, 12, 702-712.	0.7	18
40	Serotonin 5-HT7 receptor agents: Structure-activity relationships and potential therapeutic applications in central nervous system disorders. , 2011, 129, 120-148.		168
41	Arylamides hybrids of two high-affinity $led{l}f2$ receptor ligands as tools for the development of PET radiotracers. European Journal of Medicinal Chemistry, 2011, 46, 4733-4741.	2.6	35
42	Synthesis and binding assays of novel 3,3-dimethylpiperidine derivatives with various lipophilicities as $\sharp f1$ receptor ligands. Bioorganic and Medicinal Chemistry, 2011, 19, 7612-7622.	1.4	6
43	1â€Cyclohexylâ€4â€(4â€arylcyclohexyl)piperazines: Mixed σ and Human Δ <sub>8</sub> –Δ <sub>7</sub> St Isomerase Ligands with Antiproliferative and Pâ€Glycoprotein Inhibitory Activity. ChemMedChem, 2011, 6, 73-80.	erol 1.6	41
44	Studies on 1-arylpiperazine derivatives with affinity for rat 5-HT7 and 5-HT1A receptors. Journal of Pharmacy and Pharmacology, 2010, 56, 247-255.	1.2	31
45	Design and synthesis of long-chain arylpiperazines with mixed affinity for serotonin transporter (SERT) and 5-HT1A receptor. Journal of Pharmacy and Pharmacology, 2010, 57, 1319-1327.	1.2	12
46	Distribution of sigma receptors in EMT-6 cells: preliminary biological evaluation of PB167 and potential for in-vivo PET. Journal of Pharmacy and Pharmacology, 2010, 57, 1453-1459.	1.2	7
47	Tyrosine kinase inhibitors and multidrug resistance proteins: interactions and biological consequences. Cancer Chemotherapy and Pharmacology, 2010, 65, 335-346.	1.1	45
48	Interaction of the $if$ sub>2 Receptor Ligand PB28 with the Human Nucleosome: Computational and Experimental Probes of Interaction with the H2A/H2B Dimer. ChemMedChem, 2010, 5, 268-273.	1.6	32
49	Radiosynthesis and in vivo evaluation of $[11C]MC80$ for P-glycoprotein imaging. Bioorganic and Medicinal Chemistry, 2010, 18, 6489-6495.	1.4	9
50	Identification of a red-emitting fluorescent ligand for in vitro visualization of human serotonin 5-HT1A receptors. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 6628-6632.	1.0	15
51	Small-animal PET evaluation of [11C]MC113 as a PET tracer for P-glycoprotein. BMC Pharmacology, 2010, 10, .	0.4	0
52	Substrates, Inhibitors and Activators of P-glycoprotein: Candidates for Radiolabeling and Imaging Perspectives. Current Topics in Medicinal Chemistry, 2010, 10, 1703-1714.	1.0	50
53	Design, Synthesis, Radiolabeling, and in Vivo Evaluation of Carbon-11 LabeledN-[2-[4-(3-Cyanopyridin-2-yl)piperazin-1-yl]ethyl]-3-methoxybenzamide, a Potential Positron Emission Tomography Tracer for the Dopamine D4Receptors. Journal of Medicinal Chemistry, 2010, 53, 7344-7355.	2.9	12
54	LP-211 is a brain penetrant selective agonist for the serotonin 5-HT7 receptor. Neuroscience Letters, 2010, 481, 12-16.	1.0	73

#	Article	IF	CITATIONS
55	Perspectives of P-Glycoprotein Modulating Agents in Oncology and Neurodegenerative Diseases: Pharmaceutical, Biological, and Diagnostic Potentials. Journal of Medicinal Chemistry, 2010, 53, 1883-1897.	2.9	103
56	Phenylsulfonylfuroxans as Modulators of Multidrug-Resistance-Associated Protein-1 and P-Glycoprotein. Journal of Medicinal Chemistry, 2010, 53, 5467-5475.	2.9	52
57	5-HT7receptor modulators: a medicinal chemistry survey of recent patent literature (2004 – 2009). Expert Opinion on Therapeutic Patents, 2010, 20, 739-754.	2.4	13
58	Developments in fluorescent probes for receptor research. Drug Discovery Today, 2009, 14, 706-712.	3.2	72
59	Multiâ€Drugâ€Resistanceâ€Reverting Agents: 2â€Aryloxazole and 2â€Arylthiazole Derivatives as Potent BCRP or MRP1 Inhibitors. ChemMedChem, 2009, 4, 188-195.	1.6	50
60	Design, synthesis, and binding affinities of potential positron emission tomography (PET) ligands with optimal lipophilicity for brain imaging of the dopamine D3 receptor. Part II. Bioorganic and Medicinal Chemistry, 2009, 17, 758-766.	1.4	11
61	Exploring the Importance of Piperazine N-Atoms for $ f  < sub > 2 <  sub > Receptor Affinity and Activity in a Series of Analogs of 1-Cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]piperazine (PB28). Journal of Medicinal Chemistry, 2009, 52, 7817-7828.$	2.9	46
62	Synthesis and Characterization of Environment-Sensitive Fluorescent Ligands for Human 5-HT1AReceptors with 1-Arylpiperazine Structureâ€. Journal of Medicinal Chemistry, 2009, 52, 7892-7896.	2.9	22
63	Synthesis and Preclinical Evaluation of Novel PET Probes for P-Glycoprotein Function and Expression. Journal of Medicinal Chemistry, 2009, 52, 4524-4532.	2.9	52
64	ABC Pumps and Their Role in Active Drug Transport. Current Topics in Medicinal Chemistry, 2009, 9, 119-129.	1.0	58
65	1-Cyclohexylpiperazine and 3,3-Dimethylpiperidine Derivatives as Sigma-1 (σ1) and Sigma-2 (σ2) Receptor Ligands: A Review. Central Nervous System Agents in Medicinal Chemistry, 2009, 9, 205-219.	0.5	29
66	Small P-gp modulating molecules: SAR studies on tetrahydroisoquinoline derivatives. Bioorganic and Medicinal Chemistry, 2008, 16, 362-373.	1,4	78
67	4-Biphenyl and 2-naphthyl substituted 6,7-dimethoxytetrahydroisoquinoline derivatives as potent P-gp modulators. Bioorganic and Medicinal Chemistry, 2008, 16, 3732-3743.	1.4	54
68	Tritium radiolabelling of PB28, a potent sigma-2 receptor ligand: pharmacokinetic and pharmacodynamic characterization. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 2183-2187.	1.0	15
69	PB183, a sigma receptor ligand, as a potential PET probe for the imaging of prostate adenocarcinoma. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 1990-1993.	1.0	20
70	Effect of some P-glycoprotein modulators on Rhodamine-123 absorption in guinea-pig ileum. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 3741-3744.	1.0	1
71	Novel 4-(4-Aryl)cyclohexyl-1-(2-pyridyl)piperazines as î" <sub>8</sub> â^î" <sub>7</sub> Sterol Isomerase (Emopamil Binding Protein) Selective Ligands with Antiproliferative Activity. Journal of Medicinal Chemistry, 2008, 51, 7523-7531.	2.9	42
72	Bicalutamide failure in prostate cancer treatment: Involvement of Multi Drug Resistance proteins. European Journal of Pharmacology, 2008, 601, 38-42.	1.7	39

#	Article	IF	CITATIONS
73	Synthesis and Biological Evaluation of (Hetero)Arylmethyloxy- and Arylmethylamine-phenyl Derivatives as Potent P-glycoprotein Modulating Agents. Journal of Medicinal Chemistry, 2008, 51, 1415-1422.	2.9	16
74	2-[(3-Methoxyphenylethyl)phenoxy]-Based ABCB1 Inhibitors: Effect of Different Basic Side-Chains on Their Biological Properties. Journal of Medicinal Chemistry, 2008, 51, 7602-7613.	2.9	19
75	Structural Modifications of <i>N</i> -(1,2,3,4-Tetrahydronaphthalen-1-yl)-4-Aryl-1-piperazinehexanamides: Influence on Lipophilicity and 5-HT <sub>7</sub> Receptor Activity. Part III. Journal of Medicinal Chemistry, 2008, 51, 5813-5822.	2.9	67
76	5-HT1A Receptor, an Old Target for New Therapeutic Agents. Current Topics in Medicinal Chemistry, 2008, 8, 1024-1034.	1.0	83
77	Design and Evaluation of Naphthol- and Carbazole-Containing Fluorescent Ïf Ligands as Potential Probes for Receptor Binding Studies. Journal of Medicinal Chemistry, 2007, 50, 4648-4655.	2.9	30
78	High-Affinity Dopamine D <sub>3</sub> Receptor Ligands as Potential Probes for Receptor Visualization. Journal of Medicinal Chemistry, 2007, 50, 5043-5047.	2.9	43
79	Structureâ^'Activity Relationship Study on <i>N</i> -(1,2,3,4-Tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinehexanamides, a Class of 5-HT <sub>7</sub> Receptor Agents. 2. Journal of Medicinal Chemistry, 2007, 50, 4214-4221.	2.9	51
80	Bivalent ligand approach on 4-[2-(3-methoxyphenyl)ethyl]-1-(2-methoxyphenyl)piperazine: Synthesis and binding affinities for 5-HT7 and 5-HT1A receptors. Bioorganic and Medicinal Chemistry, 2007, 15, 5316-5321.	1.4	9
81	Human epididymal and prostatic tracts of vas deferens: Different contraction response to noradrenaline stimulation in isolated organ bath assay. European Journal of Pharmacology, 2007, 577, 150-155.	1.7	8
82	Arylmethyloxyphenyl Derivatives:  Small Molecules Displaying P-Glycoprotein Inhibition. Journal of Medicinal Chemistry, 2006, 49, 6607-6613.	2.9	19
83	Design, Synthesis, and Binding Affinities of Potential Positron Emission Tomography (PET) Ligands for Visualization of Brain Dopamine D3Receptors. Journal of Medicinal Chemistry, 2006, 49, 358-365.	2.9	32
84	Is the Ïf2Receptor a Histone Binding Protein?. Journal of Medicinal Chemistry, 2006, 49, 4153-4158.	2.9	59
85	Correlation between sigma2 receptor protein expression and histopathologic grade in human bladder cancer. Cancer Letters, 2006, 237, 83-88.	3.2	36
86	The sigma-2 receptor agonist PB28 inhibits calcium release from the endoplasmic reticulum of SK-N-SH neuroblastoma cells. Cell Calcium, 2006, 40, 23-28.	1.1	27
87	Cyclohexylpiperazine derivative PB28, a $\sharp f2$ agonist and $\sharp f1$ antagonist receptor, inhibits cell growth, modulates P-glycoprotein, and synergizes with anthracyclines in breast cancer. Molecular Cancer Therapeutics, 2006, 5, 1807-1816.	1.9	108
88	Methyl Substitution on the Piperidine Ring of N-[i\%-(6-Methoxynaphthalen-1-yl)alkyl] Derivatives as a Probe for Selective Binding and Activity at the if 1 Receptor. Journal of Medicinal Chemistry, 2005, 48, 8237-8244.	2.9	30
89	11C-Labeling ofN-[4-[4-(2,3-Dichlorophenyl)piperazin-1-yl]butyl]arylcarboxamide Derivatives and Evaluation as Potential Radioligands for PET Imaging of Dopamine D3Receptors. Journal of Medicinal Chemistry, 2005, 48, 7018-7023.	2.9	16
90	Antiproliferative and cytotoxic effects of some ?2 agonists and ?1 antagonists in tumour cell lines. Naunyn-Schmiedeberg's Archives of Pharmacology, 2004, 370, 106-13.	1.4	103

#	Article	IF	CITATIONS
91	Structureâ <sup>°</sup> Affinity Relationship Study onN-(1,2,3,4-Tetrahydronaphthalen-1-yl)-4-Aryl-1-Piperazinealkylamides, a New Class of 5-Hydroxytryptamine7Receptor Agents. Journal of Medicinal Chemistry, 2004, 47, 6616-6624.	2.9	62
92	4-(Tetralin-1-yl)- and 4-(Naphthalen-1-yl)alkyl Derivatives of 1-Cyclohexylpiperazine as $\ddot{l}f$ Receptor Ligands with Agonist $\ddot{l}f$ 2 Activity. Journal of Medicinal Chemistry, 2004, 47, 2308-2317.	2.9	68
93	A new method for evaluating ?2 ligand activity in the isolated guinea-pig bladder. Naunyn-Schmiedeberg's Archives of Pharmacology, 2003, 368, 106-112.	1.4	25
94	Synthesis and Structureâ <sup>-</sup> Affinity Relationships of 1-[ï‰-(4-Aryl-1-piperazinyl)alkyl]-1-aryl Ketones as 5-HT7 Receptor Ligands. Journal of Medicinal Chemistry, 2003, 46, 646-649.	2.9	53
95	Synthesis of Chiral 1-[i]%-(4-Chlorophenoxy)alkyl]-4-methylpiperidines and Their Biological Evaluation at if 1, if 2, and Sterol i 8a $^{\circ}$ i 7 Isomerase Sites. Journal of Medicinal Chemistry, 2003, 46, 2117-2124.	2.9	15
96	Structureâ°'Affinity Relationship Study onN-[4-(4-Arylpiperazin-1-yl)butyl]arylcarboxamides as Potent and Selective Dopamine D3Receptor Ligands. Journal of Medicinal Chemistry, 2002, 45, 5727-5735.	2.9	71
97	trans-4-[4-(Methoxyphenyl)cyclohexyl]-1-arylpiperazines:  A New Class of Potent and Selective 5-HT1A Receptor Ligands as Conformationally Constrained Analogues of 4-[3-(5-Methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]-1- arylpiperazines. Journal of Medicinal Chemistry. 2001. 44. 4431-4442.	2.9	26
98	A multireceptorial binding reinvestigation on an extended class of $lf$ ligands: N- $lf$ ligan	rgBT /Ove 1.4	erlock 10 Tf 5 51
99	Determination of dopamine D4 receptor density in rat striatum using PB12 as a probe. European Journal of Pharmacology, 2001, 427, 1-5.	1.7	3
100	1-Substituted-4-[3-(1,2,3,4-tetrahydro-5- or 7-methoxynaphthalen-1-yl)propyl]piperazines: influence of the N -1 piperazine substituent on 5-HT 1A receptor affinity and selectivity versus D 2 and $\hat{l}\pm 1$ receptors. Part 6. Bioorganic and Medicinal Chemistry, 2000, 8, 873-881.	1.4	15
101	Carbon-11 pb-12: an attempt to visualize the dopamine d4 receptor in the primate brain with positron emission tomography. Nuclear Medicine and Biology, 2000, 27, 707-714.	0.3	24
102	A Structureâ^'Affinity Relationship Study on Derivatives ofN-[2-[4-(4-Chlorophenyl)piperazin-1-yl]ethyl]-3-methoxybenzamide, a High-Affinity and Selective D4Receptor Ligand. Journal of Medicinal Chemistry, 2000, 43, 270-277.	2.9	28
103	1-Aryl-4-[(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)alkyl]piperazines and Their Analogues:  Influence of the Stereochemistry of the Tetrahydronaphthalen-1-yl Nucleus on 5-HT1A Receptor Affinity and Selectivity versus α1 and D2 Receptors. 5. Journal of Medicinal Chemistry, 1999, 42, 490-496.	2.9	21
104	N-[i‰-(Tetralin-1-yl)alkyl] Derivatives of 3,3-Dimethylpiperidine Are Highly Potent and Selective if 1 or if 2 Ligands. Journal of Medicinal Chemistry, 1998, 41, 3940-3947.	2.9	18
105	N-[2-[4-(4-Chlorophenyl)piperazin-1-yl]ethyl]-3-methoxybenzamide:  A Potent and Selective Dopamine D4 Ligand. Journal of Medicinal Chemistry, 1998, 41, 4903-4909.	2.9	22
106	1-(2-METHOXYPHENYL)-4-ALKYLPIPERAZINES: EFFECT OF THE N-4 SUBSTITUENT ON THE AFFINITY AND SELECTIVITY FOR DOPAMINE D4 RECEPTOR. Bioorganic and Medicinal Chemistry Letters, 1997, 7, 1327-1330.	1.0	9
107	New Ïf and 5-HT1AReceptor Ligands: ω-(Tetralin-1-yl)-n-alkylamine Derivatives. Journal of Medicinal Chemistry, 1996, 39, 176-182.	2.9	39

 $Structure \hat{a} \text{``Activity Relationship Studies on the 5-HT1AR eceptor Affinity of 1-Phenyl-4-[i‰-(î±- or) Tj ETQq0 0 0 rgBT_/Overlock 10 Tf 50 to 23 to 23 to 23 to 23 to 23 to 24 to 24 to 24 to 25 to$ 

108

#	Article	IF	CITATIONS
109	1-Aryl-4-[(1-tetralinyl)alkyl]piperazines:  Alkylamido and Alkylamino Derivatives. Synthesis, 5-HT1A Receptor Affinity, and Selectivity. 3. Journal of Medicinal Chemistry, 1996, 39, 3195-3202.	2.9	31
110	Novel Potent Ïf 1Ligands:ÂN-[ω-(Tetralin-1-yl)alkyl]piperidine Derivatives. Journal of Medicinal Chemistry, 1996, 39, 4255-4260.	2.9	7
111	High Affinity and Selectivity on 5-HT1A Receptor of 1-Aryl-4-[(1-tetralin)alkyl]piperazines. 2. Journal of Medicinal Chemistry, 1995, 38, 942-949.	2.9	92
112	Mixed 5-HT1A/D-2 activity of a new model of arylpiperazines: 1-aryl-4-[3-(1,2-dihydronaphthalen-4-yl)-n-propyl]piperazines. 1. Synthesis and structure-activity relationships. Journal of Medicinal Chemistry, 1994, 37, 99-104.	2.9	38